Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

BOSTON — Patients with non-BRCA gene mutations undergoing risk-reduction surgery to prevent tubo-ovarian cancers showed no signs of tubo-ovarian high-grade serous carcinoma or serous tubal ...

CHICAGO -- Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve progression-free survival (PFS) for the first time in a phase ...

Gemogenovatucel-T is a DNA-engineered, triple-function immunotherapy that utilizes a patient's autologous tumor cells as a source for the complete matrix of tumor-related clonal signals. Its mechanism ...

A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian cancer by nearly 80 per cent. The strategy, known as opportunistic ...

A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian ...

A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

Obesity is associated with increased surgical complications in EOC, including wound infections and intestinal problems, but not with overall survival differences. Meta-analysis showed obesity linked ...

Visakhapatnam: Doctors at KIMS, Seethammadhara successfully performed a nearly nine-hour-long advanced surgical procedure on a 42-year-old woman suffering from ovarian cancer.The procedure ...